This technology is an anticancer composition featuring a novel supramolecular compound that incorporates the fluorescent substance BODIPY into ruthenium (Ru(II)) and iridium (Ir(III)) metallacycles. This non-platinum metal-based structure inhibits cancer cell proliferation while allowing for the visualization of the drug's intracellular action site through fluorescence.
Widely used platinum-based anticancer drugs, such as cisplatin, have been associated with side effects like nephrotoxicity, as well as issues with dependency and increased drug resistance during long-term use. Furthermore, there have been no prior studies on metal supramolecular anticancer compounds derived from BODIPY-based linkers, and existing treatments have faced limitations in easily identifying where the drug acts within cancer cells.
This technology synthesizes ruthenium and iridium metallacycles linked by pyridine-functionalized BODIPY ligands to achieve superior anti-proliferative activity compared to cisplatin, while enabling direct observation of the drug's intracellular location via confocal microscopy using BODIPY fluorescence. Certain compounds selectively kill breast cancer cells, while others target brain cancer cells. Applicable to the development of treatments for lung, breast, cervical, and brain cancers, as well as health functional foods for cancer prevention, this technology serves as a next-generation metal-based anticancer candidate that simultaneously enables therapeutic efficacy and the verification of mechanisms of action.
N/A
